Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bacterial Overgrowth Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Urine Metabolites in the Diagnosis of Disease

NCT06710067
View directory record Official record
Conditions
Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
Interventions
Not listed
Lead sponsor
Luventix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Encinitas, California • Santa Monica, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Not applicable Interventional

A Trial of a Multi-Component Nutritional Supplement in Hydrogen-Dominant Small Intestinal Bacterial Overgrowth

NCT07215676
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Small Intestinal Bacterial Overgrowth
Interventions
AV1PD1A
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Treating Bacterial Overgrowth in Parkinson's Disease

NCT02470780
View directory record Official record
Conditions
Parkinson's Disease, Small Intestinal Bacterial Overgrowth
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Jul 22, 2026, 2:40 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex

NCT00956150
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Lactulose Breath Test, Rifaximin, Placebo
Procedure · Drug
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Early Phase 1 Interventional

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

NCT01878643
View directory record Official record
Conditions
Respiratory Infection, Bacterial Resistance, Respiratory Failure
Interventions
vancomycin or gentamicin, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Jul 22, 2026, 2:40 PM EDT
Not listed No phase listed Observational

Comparative Assessment of Radioisotope Glucose and Breath Test

NCT04499742
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth
Interventions
Using Isotope (Tc99m-Sulfur Colloid) to label glucose and administer this directly into duodenum.
Radiation
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Jul 22, 2026, 2:40 PM EDT
Completed No phase listed Observational

Clinical Utility of Breath Tests in GI

NCT03261856
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth, Lactose Intolerance, Fructose Intolerance, Glucose Intolerance
Interventions
Not listed
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
1,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Not applicable Interventional Results available

Gulf War Digestive Health Study

NCT00680836
View directory record Official record
Conditions
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions
Placebo, Rifaximin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
35 Years to 72 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Xylitol for Chronic Sinusitis

NCT03229551
View directory record Official record
Conditions
Chronic Rhinosinusitis, Rhinosinusitis, Sinusitis, Drain Sinus, Endoscopic Sinus Surgery, Biofilms, Bacterial Overgrowth
Interventions
Xylitol, Saline
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Jul 22, 2026, 2:40 PM EDT
Enrolling by invitation No phase listed Observational

Small Intestinal Bacterial Overgrowth: A Prospective Registry

NCT01822470
View directory record Official record
Conditions
Functional Dyspepsia, Small Intestinal Bacterial Overgrowth
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth

NCT06721884
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Interventions
Artemisia Annua Leaf, placebo
Dietary Supplement · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jul 22, 2026, 2:40 PM EDT
Terminated Phase 4 Interventional Results available

BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia

NCT05102162
View directory record Official record
Conditions
Pneumonia
Interventions
Cefepime, Meropenem, or Piperacillin/Tazobactam
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jul 22, 2026, 2:40 PM EDT
Not listed Phase 2 Interventional

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

NCT00281502
View directory record Official record
Conditions
Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
Interventions
Rifaximin (drug)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Jul 22, 2026, 2:40 PM EDT
Recruiting Phase 1 Interventional

Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®

NCT06298409
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth
Interventions
CapScan collection capsule
Device
Lead sponsor
Envivo Bio Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Not applicable Interventional Results available

Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics

NCT02223338
View directory record Official record
Conditions
Bacterial Resistance
Interventions
Ciprofloxacin, Standard Aseptic Technique
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jul 22, 2026, 2:40 PM EDT
Withdrawn Early Phase 1 Interventional

Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth

NCT03420976
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth
Interventions
Novel Supplement Based Therapy
Dietary Supplement
Lead sponsor
Atrium Innovations
Industry
Eligibility
19 Years to 84 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Oxford, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Lanreotide in the Treatment of Small Bowel Motility Disorders

NCT03012594
View directory record Official record
Conditions
Gastrointestinal Motility Disorder, Intestinal Disease
Interventions
Lanreotide
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New Hyde Park, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Jul 22, 2026, 2:40 PM EDT
Recruiting No phase listed Observational

Chronic Loose Stools Following Right-sided Hemicolectomy for Colon Cancer and the Association With Bile Acid Malabsorption and Small Intestinal Bacterial Overgrowth Using a Novel Sampling Device

NCT06927011
View directory record Official record
Conditions
Colon Cancer
Interventions
Capscan
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
20 Years to 85 Years
Enrollment
20 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 2:40 PM EDT
Completed No phase listed Observational

T2Resistance - Detection of Resistance Related Genes

NCT05231187
View directory record Official record
Conditions
Resistance Bacterial
Interventions
T2Resistance Panel
Diagnostic Test
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years and older
Enrollment
1,566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit

NCT00844831
View directory record Official record
Conditions
Constipation
Interventions
Lubiprostone
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Jul 22, 2026, 2:40 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)

NCT05288023
View directory record Official record
Conditions
Resistance Bacterial, Morality, Child Health, Implementation
Interventions
Azithromycin for Oral Suspension
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month and older
Enrollment
169,707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?

NCT00619970
View directory record Official record
Conditions
Chronic Abdominal Pain, Small Intestinal Bacterial Overgrowth
Interventions
Lactulose Breath Test, xifaxan, placebo
Procedure · Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
8 Years to 18 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota

NCT01473368
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Saccharomyces boulardii, Amoxicillin Clavulanate
Dietary Supplement · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 22, 2026, 2:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia

NCT00956397
View directory record Official record
Conditions
Functional Dyspepsia, Small Intestinal Bacterial Overgrowth, Chronic Abdominal Discomfort
Interventions
Rifaximin, Lactulose Breath Test, Placebo
Drug · Procedure
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Jul 22, 2026, 2:40 PM EDT